OncoCyte: Rises on agreement to bring cancer test to China

Burning Rock Biotech

15/12/2020 10:27

** Shares of cancer detection test developer  OCX  rise
14.6% to $2.43 premarket 
    ** Diagnostic test maker Burning Rock Biotech Ltd  BNR.O 
enters into an exclusive licensing agreement with OCX to bring
co's cancer risk stratification test DetermaRx to China
 urn:newsml:reuters.com:*:nGNX4dt5hl
    ** DetermaRx is a test which identifies non-small cell lung
cancer patients at high risk of recurrence despite curative
surgery
    ** Current avg rating on the stock is "buy"; median PT is $4
- Refinitiv IBES data
    ** Up to Monday's close, stock down 5.8% YTD

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))